The FDA is again ques­tion­ing the ef­fi­ca­cy of Capri­cor's cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, this time ahead of an ad­vi­so­ry com­mit­tee meet­ing on Wednes­day...

At a time when the fed­er­al gov­ern­ment is eval­u­at­ing re­stric­tions on med­ica­tion abor­tion, a fed­er­al judge de­ter­mined that the last ad­min­is­tra­tion im­posed too many.

A...

Af­ter two days of meet­ings, an FDA ad­vi­so­ry com­mit­tee last week vot­ed to lift re­stric­tions on six pop­u­lar health and well­ness pep­tides, set­ting aside FDA...

As drug­mak­ers pre­pare for the loom­ing bio­phar­ma patent cliff, 2026 has so far been a year for deal­mak­ing. Now, con­tract man­u­fac­tur­ers need to broad­en...

Sarep­ta Ther­a­peu­tics has found its new CEO as it seeks to re­cov­er from a calami­tous past year.

Michael Sev­eri­no will re­place the com­pa­ny’s long­time leader...